PSTV | Plus Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.1850 - 1.2350
52 Week Range	1.1500 - 2.6700
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	15,240
Average Volume	73,635
Shares Outstanding	5,896,330
Market Cap	7,016,633
Sector	Healthcare
Industry	Biotechnology
IPO Date	2001-07-11

Valuation
Profitability
Growth
Health
P/E Ratio	-0.50
Forward P/E Ratio	N/A
EPS	-2.37
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	20
Country	USA
Website	PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV's peers: ADTX, EDSA, PALI, REVB, QNRX, ZURA, CYTO, IMMX, ENVB, FWBI, DRMA, PBLA, CFRX, TARA, VCNX, MNPR, MIRO, SRZN, ATXI, HOTH, NRBO, VRAX

*Chart delayed

Analyzing fundamentals for PSTV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PSTV Fundamentals page.

Watching at PSTV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PSTV Technicals page.